Hans D. Menssen

ScholarGPS® ID: 35702973473817

Affiliation

Novartis International AG, Basel, Switzerland

Affiliation History

Field

Medicine

Discipline

Oncology

Top Specialties

Metrics Summary

Publication Count

Predicted Citations

7,633

Predicted h-index

Ranking

Publications and Citation History

Publications based on Top Specialties

Types of Publication

Publications
Books
Patents
NIH/NSF

Add Delete
Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants (journal article) Sechaud, Romain \| Gu, Helen \| Rahmanzadeh, Gholamreza \| Taylor, Amanda \| Chiparus, Ovidiu \| Sharma, Gopal Krishna \| Breitschaft, Astrid \| Menssen, Hans D. Cancer Chemotherapy and Pharmacology, volume 93, issue 5, pages 439-453 (2024). 10.1007/s00280-023-04635-3 Cite \| Source
TIM-3 Inhibitor Sabatolimab for Patients with Acute Myeloid Leukemia (AML) with Measurable Residual Disease (MRD) Detected after Allogeneic Stem Cell Transplantation (AlloSCT): Preliminary Findings from the Phase Ib/II Stimulus-AML2 Study (journal article) Zeiser, Robert \| Devillier, Raynier \| Mico', Maria Caterina \| Valcarcel, David \| Call, Simon \| Niederwieser, Christian \| Nourry, Claire \| Xu, Yunnan \| Medts, Thierry \| Guichard, Nathalie \| ... \| Polverelli, Nicola Blood, volume 142, issue Supplement 1, pages 59-59 (2023). 10.1182/blood-2023-180876 Cited by (3) \| Cite \| Source
Sabatolimab in Combination with Hypomethylating Agents (HMAs) Was Safe in Patients (Pts) with Intermediate-, High-, or Very-High-Risk Myelodysplastic Syndrome (MDS) (journal article) Garcia-Manero, Guillermo \| Lyons, Roger M. \| Nandal, Savita \| Ashraf, Mushtaq \| Thellaboina, Ramarao \| Ruckel-Kumar, Julie \| Menssen, Hans D. \| Zeidan, Amer M. Blood, volume 142, issue Supplement 1, pages 4606-4606 (2023). 10.1182/blood-2023-186490 Cite \| Source
Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis (journal article) Hartmann, Karin \| Gotlib, Jason \| Akin, Cem \| Hermine, Olivier \| Awan, Farrukh T. \| Hexner, Elizabeth \| Mauro, Michael J. \| Menssen, Hans D. \| Redhu, Suman \| Knoll, Stefanie \| ... \| Kluin-Nelemans, Hanneke C. Journal of Allergy and Clinical Immunology, volume 146, issue 2, pages 356-366.e4 (2020). 10.1016/j.jaci.2020.03.044 Cited by (41) \| Cite \| Source
Relative Bioavailability and Food Effect Evaluation for 2 Tablet Formulations of Asciminib in a 2‐Arm, Crossover, Randomized, Open‐Label Study in Healthy Volunteers (journal article) Menssen, Hans D. \| Quinlan, Michelle \| Kemp, Charisse \| Tian, Xianbin Clinical Pharmacology in Drug Development, volume 8, issue 3, pages 385-394 (2019). 10.1002/cpdd.602 Cited by (8) \| Cite \| Source
Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model (journal article) Menssen, Hans D. \| Harnack, Ulf \| Erben, Ulrike \| Neri, Dario \| Hirsch, Burkhard \| Dürkop, Horst Journal of Cancer Research and Clinical Oncology, volume 144, issue 3, pages 499-507 (2018). 10.1007/s00432-017-2564-6 Cited by (16) \| Cite \| Source
Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study (journal article) Hochhaus, A \| Masszi, T \| Giles, F J \| Radich, J P \| Ross, D M \| Gómez Casares, M T \| Hellmann, A \| Stentoft, J \| Conneally, E \| García-Gutiérrez, V \| ... \| Saglio, G Leukemia, volume 31, issue 7, pages 1525-1531 (2017). 10.1038/leu.2017.63 Cited by (226) \| Cite \| Source \| Open Access
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia (journal article) Hochhaus, Andreas \| Larson, Richard A. \| Guilhot, François \| Radich, Jerald P. \| Branford, Susan \| Hughes, Timothy P. \| Baccarani, Michele \| Deininger, Michael W. \| Cervantes, Francisco \| Fujihara, Satoko \| ... \| Druker, Brian J. New England Journal of Medicine, volume 376, issue 10, pages 917-927 (2017). 10.1056/NEJMoa1609324 Cited by (887) \| Cite \| Source \| Open Access
Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib: Results from the ENESTFreedom study. (journal article) Hochhaus, Andreas \| Masszi, Tamas \| Giles, Francis J. \| Radich, Jerald P. \| Ross, David M. \| Gómez Casares, María Teresa \| Hellmann, Andrzej \| Stentoft, Jesper \| Conneally, Eibhlin \| García Gutierrez, Valentin \| ... \| Saglio, Giuseppe Journal of Clinical Oncology, volume 34, issue 15_suppl, pages 7001-7001 (2016). 10.1200/JCO.2016.34.15_suppl.7001 Cited by (9) \| Cite \| Source
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial (journal article) Hochhaus, A \| Saglio, G \| Hughes, T P \| Larson, R A \| Kim, D-W \| Issaragrisil, S \| le Coutre, P D \| Etienne, G \| Dorlhiac-Llacer, P E \| Clark, R E \| ... \| Kantarjian, H M Leukemia, volume 30, issue 5, pages 1044-1054 (2016). 10.1038/leu.2016.5 Cited by (645) \| Cite \| Source \| Open Access
Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart (patent) Neri, Dario \| Menssen, Hans \| Menrad, Andreas \| Schliemann, Christoph Patent Number: 9289470 (2016) Cited by (1) \| Cite \| Source
Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina (journal article) Wang, Jianxiang \| Shen, Zhi-Xiang \| Saglio, Giuseppe \| Jin, Jie \| Huang, He \| Hu, Yu \| Du, Xin \| Li, Jianyong \| Meng, Fanyi \| Zhu, Huanling \| ... \| Huang, Xiaojun Blood, volume 125, issue 18, pages 2771-2778 (2015). 10.1182/blood-2014-09-601674 Cited by (81) \| Cite \| Source \| Open Access
The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer (journal article) Catania, Chiara \| Maur, Michela \| Berardi, Rossana \| Rocca, Andrea \| Giacomo, Anna Maria Di \| Spitaleri, Gianluca \| Masini, Cristina \| Pierantoni, Chiara \| González-Iglesias, Reinerio \| Zigon, Giulia \| ... \| Braud, Filippo de Cell Adhesion & Migration, volume 9, issue 1-2, pages 14-21 (2015). 10.4161/19336918.2014.983785 Cited by (47) \| Cite \| Source \| Open Access
Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd (journal article) Larson, Richard A. \| Kim, Dong-Wook \| Issaragrilsil, Surapol \| le Coutre, Philipp \| Dorlhiac Llacer, Pedro Enrique \| Etienne, Gabriel \| Clark, Richard E. \| Flinn, Ian \| Nakamae, Hirohisa \| Hochhaus, Andreas \| ... \| Hughes, Timothy P. Blood, volume 124, issue 21, pages 4541-4541 (2014). 10.1182/blood.V124.21.4541.4541 Cited by (50) \| Cite \| Source
Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart (patent) Neri, Dario \| Menssen, Hans Dietrich \| Menrad, Andreas \| Schliemann, Christoph Patent Number: 8796426 (2014) Cite \| Source
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily (journal article) Hughes, T. P. \| Hochhaus, A. \| Kantarjian, H. M. \| Cervantes, F. \| Guilhot, F. \| Niederwieser, D. \| le Coutre, P. D. \| Rosti, G. \| Ossenkoppele, G. \| Lobo, C. \| ... \| Saglio, G. Haematologica, volume 99, issue 7, pages 1204-1211 (2014). 10.3324/haematol.2013.091272 Cited by (40) \| Cite \| Source \| Open Access
Treatment-free remission (TFR) following nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath. (journal article) Mahon, Francois-Xaxier \| Baccarani, Michele \| Mauro, Michael J. \| Hughes, Timothy P. \| Saglio, Giuseppe \| Savona, Michael \| Szczudlo, Tomasz K. \| Menssen, Hans D. \| Keir, Christopher Hunt \| Walasek, Claudia \| Hochhaus, Andreas Journal of Clinical Oncology, volume 32, issue 15_suppl, pages TPS7124-TPS7124 (2014). 10.1200/jco.2014.32.15_suppl.tps7124 Cited by (19) \| Cite \| Source
Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma (journal article) Aloj, Luigi \| D’Ambrosio, Laura \| Aurilio, Michela \| Morisco, Anna \| Frigeri, Ferdinando \| Caraco’, Corradina \| Di Gennaro, Francesca \| Capobianco, Gaetana \| Giovannoni, Leonardo \| Menssen, Hans D. \| ... \| Lastoria, Secondo European Journal of Nuclear Medicine and Molecular Imaging, volume 41, issue 5, pages 867-877 (2014). 10.1007/s00259-013-2658-6 Cited by (32) \| Cite \| Source
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib (journal article) Hughes, Timothy P. \| Saglio, Giuseppe \| Kantarjian, Hagop M. \| Guilhot, François \| Niederwieser, Dietger \| Rosti, Gianantonio \| Nakaseko, Chiaki \| De Souza, Carmino Antonio \| Kalaycio, Matt E. \| Meier, Stephan \| ... \| Hochhaus, Andreas Blood, volume 123, issue 9, pages 1353-1360 (2014). 10.1182/blood-2013-06-510396 Cited by (209) \| Cite \| Source \| Open Access
Abundant in vitro expression of the oncofetal ED-B-containing fibronectin translates into selective pharmacodelivery of 131I-L19SIP in a prostate cancer patient (journal article) Locher, Ricarda \| Erba, Paola A. \| Hirsch, Burkhard \| Bombardieri, Emilio \| Giovannoni, Leonardo \| Neri, Dario \| Dürkop, Horst \| Menssen, Hans D. Journal of Cancer Research and Clinical Oncology (2014). 10.1007/s00432-013-1538-6 Cited by (23) \| Cite \| Source